Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized Neoadjuvant Treatment Regimens for Early HR+/HER2+ Breast Cancer
NCT07300215Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Bengbu Medical University
- Start
- Dec 2025
- Primary completion
- Nov 2027
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of palbociclib, exemestane in breast cancer, sponsored by First Affiliated Hospital of Bengbu Medical University. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
palbociclibexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07300215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07300215.